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Abstract
Our objective in this paper is to model the dynamics of respiratory syncytial virus in the region of
Valencia (Spain) and analyse the effect of vaccination strategies from a health-economic point of
view. Compartmental mathematical models based on differential equations are commonly used in
epidemiology to both understand the underlying mechanisms that influence disease transmission
and analyse the impact of vaccination programs. However, a recently proposed Bayesian stochas-
tic susceptible-infected-recovered-susceptible model in discrete-time provided an improved and
more natural description of disease dynamics. In this work, we propose an extension of that
stochastic model that allows us to simulate and assess the effect of a vaccination strategy that
consists on vaccinating a proportion of newborns.
MSC: 62P10.
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1. Introduction
Effective surveillance and control measures are essential to protect public health by
rapidly detecting and responding to outbreaks of infectious diseases, which pose a grow-
ing threat to human health. Shortcomings in surveillance, vaccines and treatment can
result in rising morbidity and mortality. Innovative surveillance methods have been
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recently developed in an effort to improve outbreak detection capabilities. Numerous
epidemiological models have also been proposed to simulate and analyse the impact of
different vaccination strategies from an economic and sanitary point of view. Nowa-
days, the use of models is considered as an effective tool to both represent the evolution
of diseases and assess the impact of control interventions (World Health Organization,
2016).
Most of the approaches that are currently used to study the impact of vaccination
programs fall into one of the following two categories: compartmental mathematical
models (Acedo et al., 2010; Hogan et al., 2016; Van Hoek et al., 2011; Christensen
et al., 2013; Yu et al., 2016) or computer models defined through complex schemes
of interaction (Pe´rez-Breva et al., 2014; Vannia et al., 2012; Craig et al., 2014; Poletti
et al., 2015). Compartmental models divide the population being studied into a set
of distinct compartments according to the disease status (for instance, the susceptible-
infected-recovered model divides the population into three categories) and model the
evolution of infectious diseases through changes in the number of individuals in each
compartment. They are usually based on ordinary differential equations, which imply
a continuous-time deterministic model. Besides, they are defined assuming that all the
individuals in the population are equally likely to contact any other individual (Ma and
Li, 2009; Brauer, 2008). However, contact patterns in real populations are indeed more
heterogeneous. Therefore, models involving homogeneous mixing should be replaced
by models incorporating stochastic effects (Brauer, 2008). Stochastic models are able
to accommodate the stochasticity inherent in the transmission of infection by consid-
ering that the number of individuals in each compartment is a random variable with
its associated probability distribution (Allen, 2008). In addition, stochastic models can
be easily analysed from a Bayesian viewpoint (see, for example, Gibson and Renshaw,
1998; O’Neill, 2002; Boys and Giles, 2007; Weidemann et al., 2014).
A Bayesian stochastic susceptible-infected-recovered-susceptible (SIRS) model in
discrete time has been recently proposed to model respiratory syncytial virus (RSV)
dynamics in the region of Valencia, Spain (Corbera´n-Vallet and Santonja, 2014). The
proposed model, which can be seen as a discrete time Markov chain model (Allen,
2008), does not imply mass-action mixing of individuals in the population. In addition,
the probability of disease transmission depends on a transmission rate that is allowed
to vary stochastically over time. This feature is fundamental to provide an accurate
representation of the disease dynamics.
RSV is the most important cause of lower respiratory tract illness in infants and
children worldwide. It causes repeat infections throughout life and significant disease
in pediatric and elderly population. Due to the high burden of disease globally, RSV
has been a priority for vaccine development. However, efforts to develop a safe and
effective vaccine have yet to lead to a licensed product (Anderson et al., 2013; Jones et
al., 2014; Higgings, Trujillo and Keech, 2016; Roberts et al., 2016). The epidemiology
and burden of RSV disease point to several target populations for vaccines, which may
require different vaccination strategies according to the age. The highest priority tar-
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get population are infants < 6 months of age who are at highest risk of severe disease.
The enhanced disease observed after a formalin-inactivated RSV (FI-RSV) vaccine di-
rected development of RSV vaccines toward live virus vaccines. Yet these young infants
present challenges to vaccine development. They may not respond well to a vaccine be-
cause of immature immune system, suppression of the immune response by presence of
maternal antibody, and an elevated susceptibility to disease with live RSV infection. The
second target population are children ≥ 6 months of age, both to prevent their disease
and potential transmission to younger children. The third target population are pregnant
women, since high titers of maternally derived RSV antibody have been shown to cor-
relate inversely with the incidence and severity of RSV infection in the first six months
of life. This maternal vaccination strategy would protect newborns both by placental
transfer of antibodies and by blocking transmission (Dudas and Karron, 1998). How-
ever, it would not provide protection for children beyond 4–6 months of age, and so
this strategy would be followed by direct child vaccination as maternal antibody wanes.
The last target population are the elderly, who are also at risk for severe disease. See
Higgings et al., 2016 for a current summary of RSV vaccine research and development.
Taking into account recommendations for RSV vaccine development (Anderson et
al., 2013), we present here an extension of the model proposed in (Corbera´n-Vallet and
Santonja, 2014) that allows us to simulate and assess the impact of vaccination pro-
grams. Because most efforts are directed towards immunizing infants from birth to six
months (Beeler and Eichelberger, 2013), the simulated strategy consists on vaccinating
a proportion of newborns. This strategy is similar to the one implemented in (Acedo et
al., 2010).
2. Case study
Our study focuses on weekly hospitalizations for RSV-related illnesses among children
younger than two years of age in the Spanish region of Valencia. Children aged < 2
years are the target population most problematic by possible severe complications. On
some occasions, hospitalization may be necessary, especially for RSV bronchiolitis and
pneumonia.
In particular, we have data on the number of new hospitalizations per week from
week beginning January 1st 2001 to week beginning December 20th 2004 (see Figure
1). As can be seen, RSV activity presents a clear seasonal pattern: epidemics occur
yearly between late fall and early spring.
Acedo et al. (Acedo et al., 2010) proposed a compartmental model based on ordinary
differential equations to describe these data and perform a vaccination program analy-
sis. They assumed that the sizes of the susceptible, infected, removed and vaccinated
populations were large enough so that the mixing of individuals in the population was
homogeneous. However, that is not the case, specially at the beginning of epidemics. In
162 A Bayesian stochastic SIRS model with a vaccination strategy for the analysis of...
Figure 1: Hospitalizations for respiratory syncytial virus (RSV) infection among children aged < 2 years
from week beginning January 1st 2001 to week beginning December 20th 2004 in the Spanish region of
Valencia.
addition, the transmission rate was modeled assuming the same seasonal pattern for all
the years, which is not a realistic description of the data.
Corbera´n-Vallet and Santonja (Corbera´n-Vallet and Santonja, 2014) proposed a sto-
chastic SIRS model in discrete time that provided a precise representation of the pattern
of disease. That model was also able to quite accurately identify the start of a new RSV
epidemic and its increase. However, vaccination strategies were not studied. Similar
to that study, we also confine our analysis to data collected from week beginning July
2nd, 2001 (week 27 in the time plot). Since no child was hospitalized the week before,
we can assume that the susceptible population at this time period is the population of
children aged < 2 in the region of Valencia.
It is important to emphasize here that the interest when simulating the effect of vac-
cination strategies may be to study the decrease in disease incidence. In this case study,
the available data refer to hospitalizations. Let it and yt be, respectively, the number
of infections and hospitalizations at time t. It is reasonably to assume the following
relationship:
yt ∼ Bin(it ,ρ)
where ρ is the probability of being hospitalized for RSV infection. Because informa-
tion regarding the number of newly infected children per week is not available, it is
not possible to make a statistical robust estimate of ρ. In Spain, the percentage of chil-
dren who require hospitalization for RSV is around 0.5% and 2% of the number of
infected children (Contreras, 2016; Parra et al., 2013). This percentage coincides with
the results obtained in Acedo et al. (2010). Hence, if the interest relies on analysing
the number of infections, we can assume that the number of infected children at week
t (t = 1,2, . . . ,T = 208) is given by the number of hospitalized children divided by the
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hospitalization rate:
it = yt/h
with h = 0.02 as proposed in Acedo et al. (2010).
3. Model formulation
3.1. Model formulation without vaccination
In this section we describe a Bayesian stochastic susceptible-infected-recovered-suscep-
tible (SIRS) model in discrete time that was proposed by Corbera´n-Vallet and Santonja
(2014) to study infectious disease dynamics. Let it denote the number of infected chil-
dren at week t, t = 1,2, . . . ,T . Because the population of children aged < 2 years in the
region of Valencia is finite, the observations are assumed to be Binomial distributed:
it ∼ Bin(St−1, pt) (1)
where St−1 represents the susceptible population at time t − 1; that is, the number of
individuals not yet infected with the disease at time t − 1; and pt is the probability of
becoming infected at time t.
In this discrete-time model, the number of individuals in each compartment is ex-
amined at discrete time steps. Using a fixed population, the number of susceptible (S),
infected (I), and recovered (R) individuals at time t are updated through the following
recursive equations:
St = St−1− it +bRt−1 +nt −
St−1
N
nt
It = It−1−aIt−1 + it −
It−1
N
nt
Rt = Rt−1−bRt−1 +aIt−1−
Rt−1
N
nt (2)
where a is the proportion of infected individuals that recover per unit time; b is the pro-
portion of recovered individuals who lose their immunity and become susceptible again
per unit time; nt is the number of births at time t; and N is the constant population size.
Taking into account that the average time to recover from RSV illness is 10 days and the
average time to lose immunity is 200 days, we can set a = 7 days (one week)10 days (recover time) = 0.7 and
b = 7 days (one week)200 days (time to lose immunity) = 0.035 (Acedo et al., 2010). Because the recovery time
and time to lose immunity for RSV are well-known, we have considered these values
as deterministic inputs. Otherwise, these quantities should be considered as additional
parameters of the model with their corresponding prior distribution. In addition, using
demographic data from the Spanish National Institute of Statistics (http://www.ine.es),
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the average weekly number of births in the region of Valencia for years 2001–2004 and
the population size can be set nt = 879 and N = 83,205. The flowchart diagram for the
model is described in Figure 2.
St
St−1
nt
N
nt It
It−1
nt
N
Rt
Rt−1
nt
N
it aIt−1
bRt−1
Figure 2: Flowchart of the SIRS model without vaccination. Boxes represent compartments and arrows
represent transitions between compartments, labelled by the parameters of the model.
The probability pt was modelled as:
pt = min
{
iαt−1 exp{rt}
1+ iαt−1 exp{rt}
+ c,1
}
(3)
where the mixing parameter α allows for heterogeneous mixing (homogeneous mix-
ing corresponds to α = 1 (Bjørnstad, Finkensta¨dt and Grenfell, 2002); c represents a
constant probability of becoming infected and so it accounts for the occurrence of new
cases after the disease has faded out; and exp{rt} represents the time-varying transmis-
sion rate. To accommodate the seasonal pattern observed in the dynamics of RSV, this
transmission rate is modelled by means of sine-cosine waves as:
rt = a0 +
K∑
k=1
[
a2k−1 sin
(
2kπt
52
)
+a2k cos
(
2kπt
52
)]
+ ǫt (4)
where ǫt is a random effect that represents unspecified features of week t. Note that
this formulation ensures that the probability lies in the interval 0–1 and it also takes into
account the transmissible nature of the infection. The value of K depends on the data
under study and it is set as the highest value k∗ so that the corresponding parameters
a2k∗−1 and a2k∗ are significant.
The parameters of the model are α, c, {ak}2Kk=0, and {ǫt}Tt=1. The prior distribution
assumed for parameter α is the Uniform distribution in the interval 0–1. The Uniform
distribution in the interval 0–0.01 is assigned to parameter c. In this case study, this
range of variation for c is enough to capture the probability of infection the first week of
epidemic periods. However, a wider range may be necessary in the analysis of different
diseases. Parameters {ak} are assumed to have zero mean Gaussian distributions with
standard deviations σak ; and {ǫt} are Gaussian distributed random effects with zero
mean and standard deviations σǫ. All the standard deviations in the previous equations
are assigned the Uniform distribution in the interval 0–5 (Gelman, 2006).
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3.2. Model formulation with vaccination
We propose here an extension of the model previously described to accommodate a vac-
cination strategy that consists on vaccinating a proportion of newborns. As mentioned
in the introduction section, the planning of effective vaccine strategies to protect infants
from birth to six mounth are needed. Let ˜it be the number of infected children at time
t after implementation of the vaccination program for infants. It is important to empha-
size that in this section we are working with a hypothetical scenario (since there is not
a RSV vaccination strategy implemented in the Community of Valencia), and so data
corresponding to the number of new infections are not available. Let ˜St−1 represent the
susceptible population at time t−1 and p˜t the new probability of becoming infected at
time t after introducing the RSV vaccine. We can assume then that:
˜it = ˜St−1 p˜t (5)
The number of individuals in each compartment is updated through the following
recursive equations:
˜St = ˜St−1− ˜it +b ˜Rt−1 +(1−ν)nt −
˜St−1
N
nt
˜It = ˜It−1−a ˜It−1 + ˜it −
˜It−1
N
nt
˜Rt = ˜Rt−1−b ˜Rt−1 +a ˜It−1−
˜Rt−1
N
nt
˜Vt = ˜Vt−1 +νnt −
˜Vt−1
N
nt (6)
Similar to Equations (2), a is the proportion of infected individuals that recover per
unit time; b is the proportion of recovered individuals who lose their immunity per
unit time; nt is the number of births at time t; and N is the constant population size.
Parameter ν represents the proportion of newborns that are vaccinated. We assume here
that infants receive additional booster doses if necessary to induce optimal levels of
RSV neutralizing antibody, and so vaccinated children do not evolve to the susceptible
population. Based on this assumption, there is not transition between the vaccinated
subpopulation (V ) and the susceptible one (S). The flowchart diagram for the model
with vaccination is described in Figure 3.
To estimate ˜it we need to know the value of ˜St−1 and p˜t . The first term is derived by
applying the previous recursive equations and the probability p˜t can be estimated using
the expression:
p˜t = min
{
˜iα∗t−1 exp{r∗t }
1+ ˜iα∗t−1 exp{r∗t }
+ c∗,1
}
(7)
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where α∗, c∗, and {r∗t } represent the posterior mean estimates obtained when the model
without vaccination is fitted to real data. Note that these parameters represent features
of RSV dynamics that do not depend on the number of infected children, and so it is
sensible to use these estimates to calculate p˜t . Varying the value of ν, it is possible to
find out the effect of this vaccination strategy on the number of RSV infections.
S˜t
S˜t−1
nt
N
(1−ν) nt I˜t
I˜t−1
nt
N
R˜t
R˜t−1
nt
N
i˜t aI˜t−1
bR˜t−1
V˜t
V˜t−1
nt
N
ν nt
Figure 3: Flowchart of the SIRS model with vaccination (vaccinated children do not evolve to the suscep-
tible population). Boxes represent compartments and arrows represent transitions between compartments,
labelled by the parameters of the model.
If booster doses are not planned, vaccinated children may evolve to the susceptible
population after an immunization period. In that case, the recursive equations would be
replaced by:
˜St = ˜St−1− ˜it +b ˜Rt−1 +b∗ ˜Vt−1 +(1−ν)nt−
˜St−1
N
nt
˜It = ˜It−1−a ˜It−1 + ˜it −
˜It−1
N
nt
˜Rt = ˜Rt−1−b ˜Rt−1 +a ˜It−1−
˜Rt−1
N
nt
˜Vt = ˜Vt−1−b∗ ˜Vt−1 +νnt −
˜Vt−1
N
nt (8)
where b∗ represents the proportion of vaccinated children who lose their immunity and
become susceptible per unit time. In Acedo et al. (2010), the authors assumed an im-
munization period by vaccination equal to the immunization after infection. Taking into
account this consideration, a value of b∗ equal to 0.035 could be assumed. The flowchart
diagram for this new scenario is presented in Figure 4.
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Figure 4: Flowchart of the SIRS model with vaccination (vaccinated children may evolve to the susceptible
population after an immunization period). Boxes represent compartments and arrows represent transitions
between compartments, labelled by the parameters of the model.
It is important to mention that the previously proposed model is also valid for a ma-
ternal vaccination strategy. In that case, ν would represent the proportion of newborns
whose mothers have been vaccinated and so they are protected from RSV. Since this
maternal immunization strategy does not provide complete protection, children in the
V compartment will evolve to the susceptible population after 4–6 months (Higgings et
al., 2016). The recursive equations given by (8) should then be used, with parameter b∗
adapted to this immunization period.
4. Results
In this section we describe the main results obtained in the analysis of RSV data. We
first show the results when the model without vaccines is fitted to the data. The Bayesian
analysis of the model allows us to calculate the posterior distribution of the model pa-
rameters. Because this posterior distribution is not analytically tractable, we approached
it by simulation. In particular, we obtained a random sample from it using Markov chain
Monte Carlo (MCMC) simulation techniques as implemented in the free statistical soft-
ware WinBUGS (Lunn et al., 2000). We fixed a burn-in period of 150000 iterations to
assess the convergence of MCMC chains. To reduce the correlation for the samples, we
kept one posterior sample in 25 iterations after the burn-in period until a set of 5000
iterations was obtained.
Similar to the study in Corbera´n-Vallet and Santonja (2014), we model directly the
weekly number of RSV hospitalizations as yt ∼ Bi(St−1, pt), and so pt represents the
probability of being hospitalized at time t. The posterior mean and 95% credible inter-
vals are displayed in Figure 5.
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Figure 5: Hospitalizations for RSV (solid black line) together with posterior means and 95% credible
intervals (dotted gray lines) from week beginning July 2nd 2001 to week beginning December 20th 2004 in
the Spanish region of Valencia.
Figure 6 shows the estimated transmission rate exp{rt} together with its seasonal
component, which is defined by the sum of two harmonic waves (K = 2; higher-order
frequencies were no significant). As can be seen, even though seasonality plays an
important role in disease transmission, adding random effects in the transmission rate
model to account for overdispersion is fundamental to provide a more realistic descrip-
tion of the transmission pattern.
Figure 6: Estimated transmission rate together with its seasonal component from week beginning July 2nd
2001 to week beginning December 20th 2004.
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Table 1: Posterior means and 95% credible intervals for the parameters of the model.
Parameter Mean Credible interval
α 0.80 (0.66,0.95)
c 1.54e-05 (1.26e-05,1.84e-05)
a0 −11.73 (−12.28,−11.26)
a1 −0.61 (−0.94,−0.30)
a2 −1.55 (−2.11,−1.06)
a3 −0.44 (−0.73,−0.17)
a4 −0.14 (−0.42,0.10)
It is important to mention that these results are very similar to the ones presented in
Corbera´n-Vallet and Santonja (2014). The main difference is that here we are not inter-
ested in prediction, and so we do not keep the last weeks to measure the out-of-sample
forecast accuracy. Because the data set is not exactly the same, some minor differences
are observed in the posterior distribution of the model parameters. The posterior mean
and 95% credible intervals for the parameters of the model are shown in Table 1.
Once the posterior means of the parameters of the model without vaccines have been
estimated, we can analyse the effect of the newborn vaccination strategy. As explained
in Section 3.2, parameters α, c, and {rt} represent features of RSV dynamics that do
not depend on the number of infected children, and they are used to compute both the
new probability of hospitalization once the vaccine has been implemented and the new
number of infections. In our simulation of the vaccine implementation, we assume that
there were no vaccinations before July 2nd 2001; that is, vaccines are introduced the
first week of our time frame and so we set V0 = 0.
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Figure 7: Number of real hospitalizations for RSV (solid line) and simulated numbers of hospitalizations
for two different coverage rates (percentages of vaccinated newborns), ν = 0.2 (dashed line) and ν = 0.8
(dotted line).
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Figure 7 shows the real number of hospitalizations from week beginning July 2nd
2001 to week beginning December 20th 2004 and the simulated numbers for two differ-
ent values of ν: ν = 0.2 and ν = 0.8. As expected, the number of RSV hospitalizations
decreases as the percentage of vaccinated newborns increases. Note that the value of ν
is decided by policymakers and we just set these values as an example.
Taking into account an average of 6.28 hospitalization days for every infected child
and e500 per day and child hospitalized (Acedo et al., 2010), we can estimate the total
cost of hospitalizations for the time period of study. If no child is vaccinated, the cost of
hospitalizations is approximately e13,213,120. This quantity decreases as ν increases.
The hospitalization cost for a value of ν equal to 0.2 would be around 8.5 millions of
euros, and if we set ν = 0.8, 2.5 millions of euros. Note that in order to complete the
economic analysis, we should also consider the vaccine price. For instance, (Acedo et
al., 2010) assumed a cost of e300 per child.
4.1. Comparison with a deterministic continuous-time model
In Corbera´n-Vallet and Santonja (2014), the authors compared the model described in
Section 3.1 with four alternative formulations of the SIRS model in discrete time: a
stochastic model with a deterministic seasonal transmission rate, a stochastic model
where the transmission rate was assumed to be constant over time, and the equiva-
lent deterministic formulations. The results showed that the proposed Bayesian SIRS
model in discrete-time lead to an improved goodness of fit. We compare here the re-
sults obtained with our model with those provided by a deterministic continuous-time
formulation similar to the one implemented in Acedo et al. (2010). As mentioned in the
Introduction, deterministic compartmental models in continuous-time are widely used
to assess the effect of vaccination programs. By considering only one age-group and a
constant population size, the deterministic continuous-time model without vaccines can
be formulated as:
dS
dt =−β(t)SI+bR+µ−µS
dI
dt =−aI +β(t)SI−µI
dR
dt =−bR+aI−µR (9)
where β(t) is defined as b0 + b1cos(2πt +ψ) to account for seasonality. The flowchart
of this model is shown in Figure 8.
Similar to Acedo et al. (2010), we have assumed that 1% of infants are infected in
January 1999 while the remaining 99% of infants are susceptible. We have also set
µ= 0.01074, b = 1.59, and a = 36.5. In order to estimate parameters b0, b1 and ψ, we
have used the dsolve package (Soetaert, Petzoldt and Setzer, 2010) in R (R Core Team,
2017) together with the optim function.
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Figure 8: Flowchart of the deterministic continuous-time SIRS model without vaccination.
Figure 9 compares the estimates of RSV hospitalizations obtained with both the
Bayesian stochastic SIRS model in discrete-time and its deterministic counterpart. As
can be seen, the deterministic continuous-time approach is not able to properly describe
epidemic peaks. The seasonal pattern is constant over time and it does not explain
particular features of annual epidemics. The fitting RMSE are, respectively, 2.52 and
19.09. These results highlight the importance of taking into account the stochasticity
inherent in the transmission dynamics.
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Figure 9: Real hospitalizations for RSV (solid points) and the estimates obtained with both the Bayesian
stochastic model in discrete-time (solid line) and the deterministic continuous-time model (dashed line).
If we assume that a proportion of newborns are vaccinated, the deterministic model
can be reformulated as:
dS
dt =−β(t)SI+bR+(1−ν)µ−µS
dI
dt =−aI +β(t)SI−µI
dR
dt =−bR+aI−µR
dV
dt = νµ−µV (10)
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Figure 10 displays the real number of hospitalizations from week beginning July 2nd
2001 to week beginning December 20th 2004 and the numbers simulated by the deter-
ministic continuous-time model for a coverage rate ν = 0.2. For comparative purposes,
we have also included the results provided by our model. As expected, the deterministic
model does not explain properly epidemic peaks. Nevertheless, we can conclude that
both strategies show a similar decreasing trend in the number of RSV hospitalizations
after the introduction of the vaccine.
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Figure 10: Real hospitalizations for RSV (solid line) and simulated numbers of hospitalizations provided
by both the Bayesian stochastic SIRS model (dashed line) and the deterministic continuous-time model
(dotted line) for a coverage rate ν = 0.2.
5. Conclusion
In this paper, we have described a stochastic compartmental model in discrete-time to
describe RSV dynamics in the region of Valencia. However, the model can be adapted
for other infectious diseases with (or without) a seasonal pattern and temporary (or per-
manent) immunity, replacing the transmission rate and the immunity rate according to
the nature of disease. Unlike standard formulations, this compartmental model does
not assume mass-action mixing of individuals in the population. In addition, the model
considers the stochasticity inherent in the transmission of disease and, consequently, it
provides a more realistic and accurate description of the progression of infections.
The extended model proposed in this paper provides a useful framework to address
one of the important needs in RSV incidence control: the implementation of an efficient
vaccination strategy. In particular, we have studied the effects of a vaccination strategy
that consists on vaccinating a proportion of newborns, which are the highest priority
target population. Additionally, we have pointed out how to adapt the model to simulate
a vaccination strategy targeted to pregnant women.
Nevertheless, the model has some limitations. We have assumed that the number
of births equals the number of deaths so that the total population size is constant. In
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addition, we do not consider an age structure into the formulation of the compartmental
model. It would be valuable to extend the proposed model to allow for different age
groups, for instance infants < 6 months of age and children ≥ 6 months of age, which
are considered as distinct target populations for RSV vaccines. An age-structured model
would provide an important tool to study the effects of alternative vaccination strategies.
It could demonstrate how immunization of a target population may protect others. Be-
sides, this formulation could be used to simulate the benefits of implementing a mater-
nal vaccination strategy followed by direct older infant vaccination as maternal antibody
wanes.
Note that we have only implemented a control strategy based on vaccination. How-
ever there are other possibilities such as isolation of infected individuals. This alternative
control strategy could be straightforwardly incorporated into the model by adapting the
probability of becoming infected. Under this scenario, the probability of infection at a
particular time point would depend only on a proportion of infected individuals at the
previous time point (the ones that have not been isolated). It would also be interesting
to assess the impact of both control strategies simultaneously.
Another very fruitful area for further research is the extension of the proposed model
to the spatial domain. Space can play a significant role in RSV transmission. In addition,
a spatio-temporal model may be useful to detect high-risk areas in need of more strong
intervention strategies to reduce the burden of disease.
Finally, it is worth emphasizing that we have focused here on models that have been
previously proposed to analyse the impact of vaccination strategies; in particular, we
have focused on compartmental models. However, the literature on models for the anal-
ysis of infectious disease data is vast and can be found in both statistical as well as
epidemiological journals. Comprehensive coverage of statistical models for the analy-
sis of infectious diseases in a single paper is not possible and it is beyond the scope of
this paper. Nevetheless, it would be interesting to extend common approaches to model
count time series (such as INAR models (Rao and McCabe, 2016) or p-splines (Eil-
ers, Marx and Durban, 2016)) to incorporate the impact of vaccination programs and
compare the performance of these different approaches.
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